Vaccine Technologies Market – Rising Infectious Diseases and Government Initiatives Drive Growth
The global vaccine technologies market is expanding as the rising prevalence of infectious diseases, technological advancements, government initiatives, and increased healthcare expenditure drive demand for advanced vaccine platforms. Vaccine technologies include inactivated vaccines, live attenuated vaccines, subunit vaccines, conjugate vaccines, toxoid vaccines, and nucleic acid vaccines.
The market was valued at approximately USD 50.19 billion in 2024 and is projected to reach roughly USD 155.12 billion by 2035, growing at a CAGR of approximately 10.80%. Growth is supported by rising prevalence of infectious diseases, technological advancements, government initiatives, and increased healthcare expenditure.marketresearchfuture
The inactivated vaccine segment dominated the market in 2022, while oral administration generated the most revenue. The viral diseases segment led in disease indication, and the pediatric age group was the largest market segment.
Government initiatives and funding are crucial for market growth. Governments provide financial support for vaccine R&D, enhancing the development of new technologies. Regulatory facilitation by governments accelerates vaccine approval processes, increasing market efficiency.
Financial assistance for vaccine manufacturing ensures sufficient production capacities to meet rising demand. Public awareness campaigns foster trust and acceptance of vaccines, driving market expansion.
North America held the largest market share at 45.80% in 2022, driven by significant R&D investments and new product launches. Key players include GlaxoSmithKline plc., Sanofi, Pfizer Inc., Merck & Co., Inc., Novartis AG, Emergent BioSolutions, Inc., CSL Limited, Inovio Pharmaceuticals, Inc., Bavarian Nordic, and Mitsubishi Tanabe Pharma Corporation.
Read more: Vaccine Technologies Market Size, Share, Trends
People Also Ask
Q1. What is driving the vaccine technologies market?
Rising prevalence of infectious diseases, technological advancements, government initiatives, and increased healthcare expenditure are major drivers.
Q2. Which vaccine type leads the market?
Inactivated vaccines dominated the market in 2022, while oral administration generated the most revenue.
Tags: vaccine technologies, inactivated vaccines, live attenuated vaccines, nucleic acid vaccines, infectious diseases
